Molbio Diagnostics IPO Sees Sunny GMP Today with Boosted Kostak Price!

The Molbio Diagnostics IPO is set to open for subscription on August 10, 2026, with the aim of raising approximately ₹939.7 crore. The shares will be offered in a price band of ₹768 to ₹807, providing investors the opportunity to participate in this significant public issue. Detailed subscription data will be eagerly awaited as it will reflect investor interest and engagement in the upcoming listing.

As of today, the grey market premium (GMP) for the Molbio Diagnostics IPO stands at ₹80, indicating stable sentiment among investors ahead of its listing. The consistent range of ₹80 suggests that there is a balanced demand for the share in the unofficial market. However, the Kostak rate and Subject to Sauda prices are not available at this moment, which may limit the broader assessment of speculative interest in the IPO.

The positive grey market sentiment is a promising sign for potential investors, as it reflects a certain level of confidence in the stock’s performance once it lists on the Bombay Stock Exchange (BSE) or National Stock Exchange (NSE). Indian investors are keenly observing these developments, as successful IPOs can often lead to strong initial listings, fostering an engaging investment environment. Overall, the Molbio Diagnostics IPO presents an intriguing opportunity for investors looking to capitalize on this emerging medical diagnostics player.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)